Delivery Order SPE2DB22D3301-SPE2DB25FX9FL

Award Date 1/29/25
Potential Completion Date 1/30/25
Potential Value $47K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $23,863.27, is a delivery order for 4,566,915,756 units of the drug Ondansetron ODT 4 mg tablet in 30-count packages. The contract has a firm fixed price and an ultimate completion date of January 14, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,492.25, is a delivery order for the supply of 4,566,209,153 units of the pharmaceutical drug Ondansetron HCL 4 mg tablets. The contract has an ultimate completion date of October 28, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,151.67 firm fixed-price delivery order covers the supply of 4,566,994,648 units of the drug Ondansetron HCL 4 mg tablets in 30-count packages. The contract has an ultimate completion date of January 22, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,668.98 firm fixed-price delivery order is for the supply of 4,564,762,849 units of Ondansetron ODT 4 mg tablets. The contract has an ultimate completion date of June 3, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,339.73, is a delivery order for 4,567,133,936 units of 4 mg Ondansetron HCL tablets. The award has a firm fixed price and an ultimate completion date of February 4, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,259.69 firm fixed-price delivery order contract is for the supply of Ondansetron HCL 4 mg tablets. The contract has an ultimate completion date of May 13, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,566,422,493 units of Ondansetron ODT 4 mg tablets. The firm-fixed-price, $4,353.01 delivery order contract has a completion date of November 14, 2024. AmerisourceBergen also holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical through November 2026, which covers a broad range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,777.63 firm fixed-price delivery order is for the supply of 4,566,582,363 units of Ondansetron HCL 8 mg tablets. The contract has an ultimate completion date of December 3, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,785.56 firm fixed-price delivery order is for the supply of 4,567,100,884 units of Ondansetron HCL 4 mg tablets. The contract has an ultimate completion date of January 31, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $21,607.11 Firm Fixed Price Delivery Order contract is for the supply of 4,567,146,492 units of Ondansetron HCL 4 mg tablets. The award has an ultimate completion date of February 5, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
  • SPE2DB22D3301
    Indefinite Delivery Contract
  • SPE2DB22D3301-SPE2DB25FX9FL
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $47,037.51, is a delivery order for 4,567,090,414 units of Ondansetron HCL 4 MG Tablets. The contract has a firm fixed price pricing type and a completion date of January 30, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The contract award did not utilize any set-aside designations, indicating open competition.

Generated 4/30/25, 9:51 AM